A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?
about
Intravenous immunoglobulin for the treatment of childhood encephalitisAbsence of cytokine modulation following therapeutic infusion of intravenous immunoglobulin or anti-red blood cell antibodies in a mouse model of immune thrombocytopenic purpura.Mechanisms of action of intravenous immunoglobulins.IVIg-mediated amelioration of ITP in mice is dependent on sialic acid and SIGNR1.B cells and CD22 are dispensable for the immediate antiinflammatory activity of intravenous immunoglobulins in vivo.Cellular immune dysfunction in immune thrombocytopenia (ITP).Amelioration of murine passive immune thrombocytopenia by IVIg and a therapeutic monoclonal CD44 antibody does not require the Myd88 signaling pathway.Cytokine profiles in mouse models of experimental immune thrombocytopenia reveal a lack of inflammation and differences in response to intravenous immunoglobulin depending on the mouse strain.CD44 antibody-mediated amelioration of murine immune thrombocytopenia (ITP): mouse background determines the effect of FcγRIIb genetic disruption.New aspects on the efficacy of high-dose intravenous immunoglobulins in patients with autoimmune thrombocytopenia.Role of inflammatory mediators in the pathogenesis of epilepsy.The impact of microglial activation on blood-brain barrier in brain diseases.Current proposed mechanisms of action of intravenous immunoglobulins in inflammatory neuropathies.Delayed hemolytic transfusion reaction in children with sickle cell disease.Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer.Intravenous immunoglobulins reverse acute vaso-occlusive crises in sickle cell mice through rapid inhibition of neutrophil adhesion.Heme oxygenase-1 is dispensable for the anti-inflammatory activity of intravenous immunoglobulin.CD200-dependent and nonCD200-dependent pathways of NK cell suppression by human IVIG.Targeting ischemic brain injury with intravenous immunoglobulin.Neuroprotection in stroke by complement inhibition and immunoglobulin therapy.The role of inflammation in epilepsyThe role of sialic acid as a modulator of the anti-inflammatory activity of IgG.Targeting B cells and autoantibodies in the therapy of autoimmune diseases.Type I and type II Fc receptors regulate innate and adaptive immunity.bIgG time for large eaters: monocytes and macrophages as effector and target cells of antibody-mediated immune activation and repression.Intravenous immunoglobulin for the treatment of childhood encephalitis.Role of immunoglobulin in neuronal apoptosis in a neonatal rat model of hypoxic ischemic brain injury.Differential antibody glycosylation in autoimmunity: sweet biomarker or modulator of disease activity?Sweet SIGNs: IgG glycosylation leads the way in IVIG-mediated resolution of inflammation.
P2860
Q24192957-01A03E01-625D-4520-BF80-7AB2571F94F2Q33374445-1E607929-BFAA-414A-9919-A27015A1D9AFQ33389428-A96F09B6-7E2B-4FA3-8CE1-83F3039FF456Q33399346-2FD05D7A-5D7B-4155-91FB-D3B0FF0279E8Q33403107-709D4C17-B784-48D8-85A5-0D4CCB8A9E3AQ33409710-CF73AB53-E68F-4D2D-97E3-21402217A54EQ33409741-C0466D32-5C8C-47CF-AFC8-8016DDFB5AB6Q33415298-BEBE595C-E6B3-4CE8-A95A-68D8B012A1BDQ33419269-46F82374-1518-41A4-A19F-991D00C8BBE6Q33437797-DA3AD13D-868E-4EB9-A073-BF27680A08A6Q34100649-F49262EA-B4A7-4022-8DD6-7F12FA2CD261Q34442604-E4886012-3B78-4E98-AC83-823C29EEFD92Q34620111-7E935593-EF27-4ECC-ACF1-929728EA894DQ35018501-E4B1F407-B299-4B51-9B64-B0A7F0CB2806Q35458319-04CF605E-1561-451A-AAE3-8C0CA3E4546FQ36384725-6AD5E75C-A54F-4439-B357-35C2D3647FEEQ36500575-079B57CD-43B1-4F83-86B2-DAF2251075DFQ36970338-DB0FD005-FA67-4F60-8EBE-87FE5A36825BQ37030865-C9B07E4F-DFA2-4850-94EB-7C5A1C3A9505Q37091310-9CFAF800-4400-4ED7-BFED-960F396DE641Q37816957-BAA5F6D4-F40E-4142-9B3B-EFE5993AC7FBQ37995919-1B4F1DE4-9A26-4966-9C68-2B8656B92A09Q38207937-037CB06E-13EC-4AE0-924D-6AFCBD036B55Q38232105-0131CD88-CB4F-4476-9C6D-C4FC1DD71A76Q38615353-AC7F3A8A-9375-476C-9642-68FA49EA6ACFQ41926851-90613FBD-80BC-46E0-92F7-4954B25A1AE0Q41942619-13162940-C4BE-4C43-A92C-40F2AD7D2B1AQ47804590-1395BE2A-C296-4643-9C13-9549940A9A32Q50193260-76AFCF9C-0BA6-46AD-8DF5-A723C8EE2569
P2860
A role for IL-1 receptor antagonist or other cytokines in the acute therapeutic effects of IVIg?
description
2006 nî lūn-bûn
@nan
2006 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
A role for IL-1 receptor antag ...... e therapeutic effects of IVIg?
@ast
A role for IL-1 receptor antag ...... e therapeutic effects of IVIg?
@en
type
label
A role for IL-1 receptor antag ...... e therapeutic effects of IVIg?
@ast
A role for IL-1 receptor antag ...... e therapeutic effects of IVIg?
@en
prefLabel
A role for IL-1 receptor antag ...... e therapeutic effects of IVIg?
@ast
A role for IL-1 receptor antag ...... e therapeutic effects of IVIg?
@en
P2093
P1433
P1476
A role for IL-1 receptor antag ...... e therapeutic effects of IVIg?
@en
P2093
John Freedman
John W Semple
P304
P356
10.1182/BLOOD-2006-05-023796
P407
P577
2006-09-05T00:00:00Z